Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Norovirus VP1 P-domain is the outermost part of the major capsid protein (VP1) of noroviruses, which are the leading cause of acute viral gastroenteritis worldwide (Tan & Jiang, 2014, PMID: 24501066). This domain is structurally divided into P1 and P2 subdomains, with the P2 subdomain being highly variable and containing the binding sites for histo-blood group antigens (HBGAs) (Mallagaray et al., 2019, PMID: 30643021). HBGAs serve as essential attachment factors or co-receptors for viral entry into host cells (Marionneau et al., 2002, PMID: 11831716). Because it is the most exposed portion of the virus, the P-domain is the primary target for neutralizing antibodies and is a critical focus for vaccine development, including virus-like particles (VLPs) and P-particle platforms (Jiang et al., 1992, PMID: 1310514). Therapeutic strategies targeting the P-domain aim to inhibit viral infection by using small-molecule HBGA mimetics or monoclonal antibodies that sterically block the receptor-binding interface (Koromyslova et al., 2017, PMID: 28424244). However, the high degree of genetic diversity and rapid antigenic drift within the P-domain present significant challenges for the development of broadly protective vaccines and antivirals (Debbink et al., 2012, PMID: 22933273). Current research focuses on identifying conserved epitopes within the P-domain to create cross-reactive therapeutics that can overcome the challenges of viral evolution (Lindesmith et al., 2012, PMID: 22532665).
Competitive inhibition of host cell attachment by blocking the P-domain's interaction with histo-blood group antigens (HBGAs).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Norovirus major capsid protein VP1 protruding domain (VP1 P-domain) (VP1 P-domain).